Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor.[3][4][5][6][7] It is part of a nirmatrelvir/ritonavir combination used to treat COVID-19 and sold under the brand name Paxlovid.[8]
Despite earning billions for Pfizer (e.g. $4.1B in Q1 2022 alone[9][10]), research into the efficacy of nirmatrelvir/ritonavir over placebo has shown mixed results (see Research below).
^"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Archived from the original on 3 April 2022. Retrieved 13 May 2022.
^"Notice: Nirmatrelvir (COVID-19) added to Prescription Drug List (PDL)". Health Canada. 17 January 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
^ abCite error: The named reference Owen was invoked but never defined (see the help page).
^Şimşek-Yavuz S, Komsuoğlu Çelikyurt FI (August 2021). "Antiviral treatment of COVID-19: An update". Turkish Journal of Medical Sciences. 51 (SI-1): 3372–3390. doi:10.3906/sag-2106-250. PMC 8771049. PMID 34391321. S2CID 237054672.
^Ahmad B, Batool M, Ain QU, Kim MS, Choi S (August 2021). "Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations". International Journal of Molecular Sciences. 22 (17): 9124. doi:10.3390/ijms22179124. PMC 8430524. PMID 34502033.
^"Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death" (Press release). Pfizer. 14 December 2021. Archived from the original on 26 December 2021. Retrieved 25 December 2021 – via Business Wire.
^Vandyck K, Deval J (August 2021). "Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection". Current Opinion in Virology. 49: 36–40. doi:10.1016/j.coviro.2021.04.006. PMC 8075814. PMID 34029993.
^"Paxlovid- nirmatrelvir and ritonavir kit". DailyMed. Archived from the original on 31 December 2021. Retrieved 30 December 2021.
^"Pfizer pulls Q1 surprise with $4.1B in sales of COVID products, despite plummeting demand". FiercePharma. Retrieved 8 May 2024.
^"Pfizer cuts earnings, revenue guidance as Covid sales slump". CNBC. Retrieved 8 May 2024.
Nirmatrelvir is an antiviral medication developed by Pfizer which acts as an orally active 3C-like protease inhibitor. It is part of a nirmatrelvir/ritonavir...
enhance their blood concentration. In December 2021, the combination of nirmatrelvir and ritonavir was granted emergency use authorization by the US Food...
Caffeine/ergotamine — treatment of headaches, such as migraine headache. Nirmatrelvir/ritonavir (Paxlovid) — granted emergency use authorization (EUA) by the...
sequence or identified the screening of compound libraries. For example, Nirmatrelvir is an orally-active small molecule drug derived from lufotrelvir, a modified...
Bao H, Feng H, Mei S, Chen P, et al. (February 2023). "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of...
activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions". Antimicrobial Agents and Chemotherapy. 67...
7832, intravenous favipiravir, and the combination of molnupiravir plus nirmatrelvir/ritonavir. AGILE differs from other trial platforms in several ways....
COVID-19 including several variant strains, but unlike the related drug nirmatrelvir it is not orally active and must be administered by intravenous infusion...
condition. The antivirals tested in the study will be molnupiravir and nirmatrelvir/ritonavir (Paxlovid). In December 2022, results from the trial showed...
manufacture the generic version of Pfizer's oral COVID-19 treatment, nirmatrelvir. In July 2022, Hengdian Entertainment, one of the listed companies of...